Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

Abstract

Background: Identification of membrane proteins differentially expressed on tumor cells is a key step in drug development. The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein belonging to the immunoglobulin superfamily. Here, we explore the prognostic role CEACAM6 expression on patient outcome in cancer. Methods: A systematic search for studies evaluating the association between tumor expression of CEACAM6 and overall survival (OS) and disease-free survival (DFS) was performed. Hazard ratios (HR) were pooled in a meta-analysis using generic inverse variance and random effect modeling. Subgroup analyses were conducted based on tumor type and method of HR extraction. Results: Sixteen studies met the inclusion criteria. CEACAM6 expression was associated with worse OS [HR = 1.96, 95% confidence interval (CI) = 1.51–2.53], and DFS (HR = 2.49, 95% CI = 2.01–3.07) with subgroup analysis showing no significant differences between disease site subgroups. Conclusions: High expression of CEACAM6 is associated with worse OS and DFS in different malignancies. CEACAM6 is a target for the future development of novel therapeutics.

Identification and characterization of stromal-like cells with CD207+/low CD1a+/low phenotype derived from histiocytic lesions – a perspective in vitro model for drug testing

“…Furthermore, the CEACAM6 molecule, acknowledged as a prognostic indicator for survival and recurrence in various types of cancer, was also overexpressed in LCH lesions [ 18 ]. However, CEACAM6 role is not only restricted to cancer progression, but this molecule can also act as an immune checkpoint inhibitor in tumours [ 41 ]. In addition, CD1D—a cell surface glycoprotein playing a critical role in presenting lipid antigens to natural killer (NK) cells, was found to be expressed by a population of LCH 207 + cells noted in the lesion.…”

Tripartite motif–containing 9 promoted proliferation and migration of bladder cancer cells through CEACAM6-Smad2/3 axis

“…The aberrant expression of CEACAM6 leads to the development of human malignancies (Duxbury et al 2004 ; Poola et al 2006 ). Recently, CEACAM6 has been identified as a prognostic factor of survival and recurrence in many tumors given its involvement on cell differentiation, growth, invasiveness, metastasis and drug resistance (Burgos et al 2022 ). For instance, CEACAM6 induces EMT and mediates invasion and metastasis in pancreatic cancer, gastric cancer via PI3K/AKT signaling pathway (Chen et al 2013 ; Zang et al 2014 ).…”

A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC

“…Analysis of biomarkers was limited to circulating CEACAM6 levels. CEACAM6 overexpression is generally associated with worse OS and DFS in a variety of solid tumors, 18 and serum CEACAM6 has been reported as a potential biomarker in pancreatic adenocarcinoma and plasma cell disorders. 19 , 20 , 21 In addition, Cao et al.…”